An observational study in Cerebrovascular Disorders, Brain Tumours and Alzheimer Dementia, sponsored by Beijing Tiantan Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-24.
Sponsored by Beijing Tiantan Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Cerebrovascular Disorders by Beijing Tiantan Hospital — 10 open to participants now, 10 under way, 1 of them phase 3. Cerebrovascular Disorders · Beijing Tiantan Hospital.
Among the 12 studies in Cerebrovascular Disorders by Beijing Tiantan Hospital, this one is one of 5 that started in 2025, is one of 5 observational ones, and was the 12th registered.
450 studies on the registry are indexed under Cerebrovascular Disorders; 126 are open to participants now.
Browse Cerebrovascular Disorders studies →10 of the 12 studies in Cerebrovascular Disorders by Beijing Tiantan Hospital are open now, in 1 country. Recruiting first, the newest first:
Beijing Tiantan Hospital · Sites in China
Ages 1–80
Beijing Tiantan Hospital · Sites in China
Ages 18–80
Beijing Tiantan Hospital · Sites in China
Ages 18–80 · Healthy volunteers
Beijing Tiantan Hospital · Sites in China
Ages 50–75 · Healthy volunteers
Beijing Tiantan Hospital · Sites in China
Ages 6–90 · Healthy volunteers
By country, each count listing its studies:
Of the 94 Cerebrovascular Disorders studies recruiting now, 54 (57%) set no upper age limit and 12 (13%) stop at 75 or younger; 10 take children under 18; 19 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2019; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 447 across 146 observational studies indexed under Cerebrovascular Disorders.
Median enrollment 328 across the 7 interventional studies, 1,000 across the 5 observational. Of the 1 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Beijing Tiantan Hospital is the lead sponsor of 494 studies on the registry; 298 are open to participants now.
1 of the studies in Cerebrovascular Disorders by Beijing Tiantan Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06925178Beijing Tiantan HospitalMulti-Modality Imaging Standard Cohort Of Cerebrovascular Disease | 2027-09-30 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies in Cerebrovascular Disorders by Beijing Tiantan Hospital, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Environmental pollutants have emerged as a major global health concern, with growing evidence linking exposure to both traditional contaminants such as heavy metals (lead, mercury, cadmium, arsenic) and novel pollutants-including micro- and nanoplastics, per- and polyfluoroalkyl substances (PFAS), antibiotics, and endocrine-disrupting chemicals-to adverse neurological outcomes. These pollutants can cross or disrupt the blood-brain barrier, accumulate in neural tissue, and trigger oxidative stress, inflammation, epigenetic modifications, and metabolic reprogramming.
Brain tumours and cerebrovascular diseases represent two major categories of neurosurgical disorders with high morbidity and mortality. However, their interaction with environmental pollutant exposure remains poorly understood. Recent studies suggest that pollutant-induced molecular alterations, such as aberrant DNA methylation, lipid metabolism disruption, and neurovascular endothelial dysfunction, may contribute to tumour initiation, malignant progression, aneurysm formation, and stroke occurrence.
Given the increasing human exposure to these pollutants and the lack of large-scale clinical data, it is urgent to establish a systematic investigation in neurosurgical patients. This study aims to profile pollutant exposure (heavy metals, PFAS, microplastics, and other novel contaminants) using multi-biospecimen analysis (blood, urine, hair, tumour and peri-tumour tissues), and to explore their mechanistic links to the pathogenesis of brain tumours and cerebrovascular diseases. The findings are expected to provide new evidence for understanding environment-brain interactions and to identify potential biomarkers for disease risk stratification and prevention.
Patients with brain tumours or cerebrovascular diseases who need surgical resection.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Overall Survival (OS)
OS is defined as the time from the sample collection date to death due to any cause. All other participants will be censored at the last date known to be alive.
Time frame: Until death or study completion (24 months)
Progression-Free Survival (PFS)
PFS is defined as the duration of time from sample collection date to time of progression or death, whichever occurs first.
Time frame: Until progression or death or study completion (24 months)
modified Rankin Scale (mRS)
Patients' mRS scores at 90 days after sample collection.
Time frame: 90 days after sample collection
Plan to share: Undecided
No publications or documents are linked to this record.
Started Aug 2025 (actual). Primary completion is estimated for Dec 2025, 4 months after the start.
Of 77 non-industry observational studies under Cerebrovascular Disorders, half reached primary completion within 103 months of starting (the median), counting those still running; a quarter within 57 and three quarters within 339. This study's planned 4 months is below that.
Counting every sponsor, half of 81 studies reached it within 101 months; a quarter within 57 and three quarters within 339.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.